Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | SVP, CHIEF ACCOUNTING OFFICER | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,199 |
Ending reported balance
After 2026-06-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-17 · Exercise / conversion · Acquired 19,686 · Balance 89,885 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. Row 2 · 2026-06-17 · Sale · Disposed 19,686 · Balance 70,199 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.69 · Expires 2034-02-14 | Direct | 15,314 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Exercise / conversion · Disposed 19,686 · Balance 15,314 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. F2: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026.
F2: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,686 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001707685-26-000010 · form4-06222026_050603.xml · derivative · entry 3 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,314 Underlying: Common Stock · 19,686 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. F2 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 19,686 | $75.56 | $1,487,474.16 |
DisclosureSEC source: 0001707685-26-000010 · form4-06222026_050603.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,199 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 19,686 | $25.69 | $505,733.34 |
DisclosureSEC source: 0001707685-26-000010 · form4-06222026_050603.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,494 | $69.36 | $172,983.84 |
DisclosureSEC source: 0001707685-26-000008 · form4-02202026_050211.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,199 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and the vesting of 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,034 | $76.45 | $79,049.30 |
DisclosureSEC source: 0001707685-26-000006 · form4-01122026_050111.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,693 F1 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,900 RSUs from a January 7, 2022 grant of 11,600 RSUs. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,235 | $77.45 | $95,650.75 |
DisclosureSEC source: 0001707685-26-000004 · form4-01082026_050123.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,727 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a January 5, 2023 grant of 14,000 RSUs. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,381 | $76.95 | $106,267.95 |
DisclosureSEC source: 0001707685-26-000004 · form4-01082026_050123.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,962 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a January 3, 2025 grant of 14,000 RSUs. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 33,125 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001707685-26-000002 · form4-01062026_050124.xml · derivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,125 Underlying: Common Stock · 33,125 shares Expires 2036-01-01 F3 · derivative.exercise_date: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 13,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001707685-26-000002 · form4-01062026_050124.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,343 F1 · shares: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. F2 · balance_after: Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025, and 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 878 | $50.12 | $44,008.87 |
DisclosureSEC source: 0001415889-25-005139 · form4-02212025_050215.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,564 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and the vesting of 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 879 | $50.10 | $44,034.38 |
DisclosureSEC source: 0001415889-25-005139 · form4-02212025_050215.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,442 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and the vesting of 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,662 | $44.50 | $73,959.00 |
DisclosureSEC source: 0001415889-25-001295 · form4-01102025_050111.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,321 F2 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,175 RSUs from January 6, 2021 grants totaling 8,700 RSUs and the vesting of 2,900 RSUs from a January 7, 2022 grant of 11,600 RSUs. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,291 | $45.34 | $58,533.94 |
DisclosureSEC source: 0001415889-25-001295 · form4-01102025_050111.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,983 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a January 5, 2023 grant of 14,000 RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001021 · form4-01072025_050113.xml · derivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2025-01-02 F3 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001021 · form4-01072025_050113.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,274 F1 · shares: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026. F2 · balance_after: Includes 445 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2024, and 401 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2024. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,695 | $0.00 Strike: $51.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028286 · form4-12042024_051203.xml · derivative · entry 8 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,695 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024. F6 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,105 | $0.00 Strike: $51.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028286 · form4-12042024_051203.xml · derivative · entry 7 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,695 Underlying: Common Stock · 3,105 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024. F6 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,776 | $52.45 | $250,501.20 |
DisclosureSEC source: 0001415889-24-028286 · form4-12042024_051203.xml · nonDerivative · entry 6 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,428 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.15 to $52.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,919 | $51.53 | $511,126.07 |
DisclosureSEC source: 0001415889-24-028286 · form4-12042024_051203.xml · nonDerivative · entry 5 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,204 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.15 to $52.11 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 14,695 | $51.00 | $749,445.00 |
DisclosureSEC source: 0001415889-24-028286 · form4-12042024_051203.xml · nonDerivative · entry 4 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 608 | $52.24 | $31,761.92 |
DisclosureSEC source: 0001415889-24-028286 · form4-12042024_051203.xml · nonDerivative · entry 3 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,428 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.16 to $52.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,497 | $51.34 | $128,195.98 |
DisclosureSEC source: 0001415889-24-028286 · form4-12042024_051203.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,036 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.15 to $52.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,105 | $51.00 | $158,355.00 |
DisclosureSEC source: 0001415889-24-028286 · form4-12042024_051203.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004163 · form4-02162024_050204.xml · derivative · entry 3 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-02-14 F3 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004163 · form4-02162024_050204.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,428 F2 · shares: Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004163 · form4-02162024_050204.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,528 F1 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 318 | $27.25 | $8,665.75 |
DisclosureSEC source: 0001415889-24-002169 · form4-02012024_090204.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,528 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 1,020 RSUs from a January 29, 2020 grant of 4,080 RSUs. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,653 | $29.01 | $47,961.46 |
DisclosureSEC source: 0001415889-24-000921 · form4-01102024_090117.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,846 F3 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,175 RSUs from a January 6, 2021 grant of 8,700 RSUs and the vesting of 2,900 RSUs from a January 7, 2022 grant of 11,600 RSUs. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,188 | $28.64 | $34,024.68 |
DisclosureSEC source: 0001415889-24-000921 · form4-01102024_090117.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,499 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a January 5, 2023 grant of 14,000 RSUs. F2 · balance_after: Includes 327 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2023 and 301 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2023. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 371 | $33.02 Strike: $33.02 | $12,250.42 |
DisclosureSEC source: 0001415889-23-006833 · form4-04252023_080440.xml · derivative · entry 7 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 371 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,321 | $33.02 Strike: $33.02 | $142,679.42 |
DisclosureSEC source: 0001415889-23-006833 · form4-04252023_080440.xml · derivative · entry 6 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,321 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 20 | $55.64 | $1,112.80 |
DisclosureSEC source: 0001415889-23-006833 · form4-04252023_080440.xml · nonDerivative · entry 5 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,059 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 351 | $55.09 | $19,337.29 |
DisclosureSEC source: 0001415889-23-006833 · form4-04252023_080440.xml · nonDerivative · entry 4 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,079 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.50 to $55.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 371 | $33.02 | $12,250.42 |
DisclosureSEC source: 0001415889-23-006833 · form4-04252023_080440.xml · nonDerivative · entry 3 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,321 | $55.05 | $237,875.80 |
DisclosureSEC source: 0001415889-23-006833 · form4-04252023_080440.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,059 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.50 to $55.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,321 | $33.02 | $142,679.42 |
DisclosureSEC source: 0001415889-23-006833 · form4-04252023_080440.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:21 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,688 | $40.45 Strike: $40.45 | $189,629.60 |
DisclosureSEC source: 0001415889-23-005666 · form4-03312023_080336.xml · derivative · entry 4 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,688 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:21 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,441 | $47.78 | $68,844.06 |
DisclosureSEC source: 0001415889-23-005666 · form4-03312023_080336.xml · nonDerivative · entry 3 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,059 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.50 to $48.285 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:21 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,247 | $47.80 | $155,200.11 |
DisclosureSEC source: 0001415889-23-005666 · form4-03312023_080336.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.50 to $48.285 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:21 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,688 | $40.45 | $189,629.60 |
DisclosureSEC source: 0001415889-23-005666 · form4-03312023_080336.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,729 | $33.02 Strike: $33.02 | $321,251.58 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · derivative · entry 10 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371 Underlying: Common Stock · 9,729 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,929 | $33.02 Strike: $33.02 | $558,995.58 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · derivative · entry 9 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,321 Underlying: Common Stock · 16,929 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 300 | $46.01 | $13,803.00 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · nonDerivative · entry 8 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,059 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,954 | $45.38 | $224,833.33 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · nonDerivative · entry 7 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,359 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,475 | $44.71 | $200,058.46 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · nonDerivative · entry 6 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,313 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $43.97 to $44.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 9,729 | $33.02 | $321,251.58 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · nonDerivative · entry 5 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 200 | $46.01 | $9,201.00 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · nonDerivative · entry 4 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,059 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,780 | $45.42 | $398,748.97 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · nonDerivative · entry 3 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,259 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.995 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,949 | $44.72 | $355,461.00 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,039 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $43.97 to $44.96 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 16,929 | $33.02 | $558,995.58 |
DisclosureSEC source: 0001415889-23-005566 · form4-03292023_080330.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, FINANCE & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.